Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 657Carcinoma, Renal Cell 385Carcinoma, Non-Small-Cell Lung 243Urinary Bladder Neoplasms 235Breast Neoplasms 221Melanoma 193Ovarian Neoplasms 192Neoplasms 178Colorectal Neoplasms 161Kidney Neoplasms 152Neoplasm Metastasis 131Carcinoma, Transitional Cell 127Pancreatic Neoplasms 124Lung Neoplasms 121Stomach Neoplasms 114Squamous Cell Carcinoma of Head and Neck 107Sarcoma 99Head and Neck Neoplasms 89Uterine Cervical Neoplasms 88Carcinoma, Hepatocellular 80Triple Negative Breast Neoplasms 76Esophageal Neoplasms 76Endometrial Neoplasms 75Colonic Neoplasms 64Wilms Tumor 56Small Cell Lung Carcinoma 55Carcinoma, Ovarian Epithelial 48Neuroblastoma 47Liver Neoplasms 46Testicular Neoplasms 45

Interventions

proxalutamide 1Pluvicto 1Androgen Receptor Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Metastatic Castrate Resistant Prostate Cancer (mCRPC) × Genitourinary × Clear all
NCT06943495 2025-09-09

PRODIGY-2

CHU de Quebec-Universite Laval

Phase 1 Recruiting
60 enrolled
Genitourinary

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT02826772 2020-03-17

Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

Suzhou Kintor Pharmaceutical Inc,

Phase 1 Completed
40 enrolled
Genitourinary

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡